It engages in developing, commercializing and marketing products. The subjects will have long-term access to the test, allowing them to test every six months for up to two years. is a medical technology company in Dermatology and Plastic Surgery.
STRATA SKIN SCIENCES TRIAL
Under the agreement, Biocept will provide its Target Selector platform, a liquid biopsy test, at free of cost to all the patients enrolled in Catalyst’s ongoing phase III clinical trial designed to demonstrate the safety and efficacy of Firdapse. Molecular diagnostics company, Biocept, has announced collaboration with Catalyst Pharmaceuticals, a biopharmaceutical company currently developing Firdapse ® (amifampridine phosphate) for the treatment of LEMS (lambert eaton myasthenic syndrome), a rare neuromuscular disorder associated with small cell lung cancer (SCLC). In exchange, STRATA will pay an annual license fee and a sales commission on each product to Ellipse.Įllipse designs and develops laser-based dermatologic solutions, while STRATA is a medical technology company focused on the therapeutic and diagnostic dermatology market. 1-3 Quick and virtually painless without the troublesome side effects of other treatment options, it’s simply a better way to long-lasting results. The XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis and vitiligo.
Use the PitchBook Platform to explore the full. Pursuant to the agreement, STRATA will distribute Ellipse lasers for three years, extendable up to five years subject to achieving minimum sales target. Lighting the way to better skin that lasts. Information on stock, financials, earnings, subsidiaries, investors, and executives for STRATA Skin Sciences.
0 kommentar(er)
